utah med prod - UTMD

UTMD

Close Chg Chg %
62.86 -1.22 -1.94%

Closed Market

61.64

-1.22 (1.94%)

Volume: 12.90K

Last Updated:

Feb 6, 2026, 4:00 PM EDT

Company Overview: utah med prod - UTMD

UTMD Key Data

Open

$62.90

Day Range

61.00 - 62.90

52 Week Range

51.27 - 64.46

Market Cap

$198.24M

Shares Outstanding

3.20M

Public Float

2.98M

Beta

0.34

Rev. Per Employee

N/A

P/E Ratio

18.05

EPS

$2.68

Yield

194.88%

Dividend

$0.31

EX-DIVIDEND DATE

Dec 16, 2025

SHORT INTEREST

N/A

AVERAGE VOLUME

12.96K

 

UTMD Performance

1 Week
 
0.95%
 
1 Month
 
2.90%
 
3 Months
 
7.39%
 
1 Year
 
2.98%
 
5 Years
 
-32.70%
 

UTMD Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 1
Full Ratings ➔

About utah med prod - UTMD

Utah Medical Products, Inc. engages in the manufacturing, developing, and marketing of disposable and reusable medical devices. It focuses on the healthcare of women and babies. The firm's products are used for blood pressure monitoring and blood collection, electrosurgery, gynecology, neonatal critical care, perinatology, and urology. The company was founded on April 21, 1978 and is headquartered in Midvale, UT.

UTMD At a Glance

Utah Medical Products, Inc.
7043 South 300 West
Midvale, Utah 84047-1048
Phone 1-801-566-1200 Revenue 38.52M
Industry Medical Specialties Net Income 11.29M
Sector Health Technology Employees N/A
Fiscal Year-end 12 / 2026
View SEC Filings

UTMD Valuation

P/E Current 18.046
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 16.065
Price to Sales Ratio 4.707
Price to Book Ratio 1.495
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA N/A
Enterprise Value to Sales N/A
Total Debt to Enterprise Value N/A

UTMD Efficiency

Revenue/Employee N/A
Income Per Employee N/A
Receivables Turnover 10.937
Total Asset Turnover 0.314

UTMD Liquidity

Current Ratio 37.622
Quick Ratio 34.568
Cash Ratio 33.008

UTMD Profitability

Gross Margin 51.597
Operating Margin 29.60
Pretax Margin 36.63
Net Margin 29.299
Return on Assets 9.21
Return on Equity 9.536
Return on Total Capital N/A
Return on Invested Capital N/A

UTMD Capital Structure

Total Debt to Total Equity N/A
Total Debt to Total Capital N/A
Total Debt to Total Assets N/A
Long-Term Debt to Equity N/A
Long-Term Debt to Total Capital N/A
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Utah Med Prod - UTMD

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
52.28M 50.22M 40.90M 38.52M
Sales Growth
+6.58% -3.93% -18.56% -5.83%
Cost of Goods Sold (COGS) incl D&A
26.50M 25.88M 18.82M 18.64M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
7.08M 6.37M 2.85M 2.95M
Depreciation
665.00K 676.00K 781.00K 826.00K
Amortization of Intangibles
6.42M 5.69M 2.06M 2.13M
COGS Growth
+6.94% -2.35% -27.25% -0.96%
Gross Income
25.78M 24.35M 22.08M 19.88M
Gross Income Growth
+6.21% -5.56% -9.32% -9.98%
Gross Profit Margin
+49.31% +48.47% +53.98% +51.60%
2022 2023 2024 2025 5-year trend
SG&A Expense
5.32M 5.91M 6.34M 8.47M
Research & Development
493.00K 560.00K 813.00K 668.00K
Other SG&A
4.83M 5.35M 5.53M 7.80M
SGA Growth
-0.95% +11.09% +7.38% +33.54%
Other Operating Expense
- - - -
-
Unusual Expense
- 670.00K 1.66M 2.14M
EBIT after Unusual Expense
19.79M 16.78M 13.59M 11.40M
Non Operating Income/Expense
869.00K 3.31M 3.21M 2.71M
Non-Operating Interest Income
- 661.00K 3.04M 3.37M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - - -
-
Interest Expense Growth
- - - -
-
Gross Interest Expense
- - - -
-
Interest Capitalized
- - - -
-
Pretax Income
20.66M 20.09M 16.80M 14.11M
Pretax Income Growth
+8.38% -2.76% -16.36% -16.02%
Pretax Margin
+39.52% +40.00% +41.08% +36.63%
Income Tax
4.19M 3.45M 2.93M 2.82M
Income Tax - Current - Domestic
- 4.63M 4.08M 3.27M
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- (446.00K) (621.00K) (340.00K)
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
16.47M 16.64M 13.87M 11.29M
Minority Interest Expense
- - - -
-
Net Income
16.47M 16.64M 13.87M 11.29M
Net Income Growth
+11.39% +0.98% -16.60% -18.65%
Net Margin Growth
+31.51% +33.12% +33.92% +29.30%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
16.47M 16.64M 13.87M 11.29M
Preferred Dividends
- - - -
-
Net Income Available to Common
16.47M 16.64M 13.87M 11.29M
EPS (Basic)
- 4.5293 4.5839 3.9606
EPS (Basic) Growth
- +11.70% +1.21% -13.60%
Basic Shares Outstanding
- 3.64M 3.63M 3.50M
EPS (Diluted)
4.5218 4.5738 3.9606 3.4833
EPS (Diluted) Growth
+11.91% +1.15% -13.41% -12.05%
Diluted Shares Outstanding
3.64M 3.64M 3.50M 3.24M
EBITDA
27.54M 24.80M 18.58M 14.35M
EBITDA Growth
+5.18% -9.94% -25.10% -22.74%
EBITDA Margin
+52.68% +49.39% +45.42% +37.26%

Utah Med Prod in the News